The Effectiveness of Bupivacaine and Bupivacaine+Dexmedetomidine Combination in Transversus Abdominis Plane* Block

Colorectal Cancer Clinical Trial

— TAP  

Official title:

Comparison of the Effectiveness of Bupivacaine and Bupivacaine+Dexmedetomidine Combination in Transversus Abdominis Plane* Block in Colorectal Cancer Surgery

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06370949
• Other study ID #: 2024-01/17
• Status: Not yet recruiting
• Start date: May 1, 2024
• Est. completion date: November 30, 2024

Study information

• Verified date: April 2024
• Source: Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
• Contact: Beyza Seker, MD
• Phone: 05442208075
• Email: drbeyzaseker[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Transversus abdominis plane (TAP) block is an anesthesia method that provides somatic analgesia to the anterior and lateral abdominal walls. Thus, TAP block is widely implemented in perioperative management of colorectal cancer patients. Researchers aimed to evaluate the analgesic effectiveness and duration of effect of dexmedetomidine added to bupivacaine in the TAP block applied in colorectal cancer surgeries.

Description:

Transversus abdominis plane (TAP) block is an anesthesia method that provides somatic analgesia to the anterior and lateral abdominal walls. With the increasing use of ultrasound guidance during peripheral nerve blocks, trunk blocks such as the transversus abdominis plane (TAP) block are widely used for analgesia after abdominal surgery. The advantages of TAP block include being less invasive than epidural analgesia, lower incidence of hypotension, and shorter hospital stay. Due to these advantages, TAP block has become a widely preferred method. Researchers aimed to evaluate the analgesic effectiveness and duration of effect of dexmedetomidine added to bupivacaine in the TAP block applied in colorectal cancer surgeries. The study will be conducted in a tertiary oncology hospital in Turkey and 84 colorectal cancer patients will be included.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 84
• Est. completion date: November 30, 2024
• Est. primary completion date: September 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• colorectal cancer diagnosis
• undergoing colorectal cancer surgery

Exclusion Criteria:

• allergic reaction to local anesthetics
• bleeding anomalies
• infection in TAP block area

Related Conditions & MeSH terms

• Colorectal Cancer
• Colorectal Neoplasms

Intervention

Drug:
• Bupivacain
Ultrasonography (USG) guided bilateralTAP block:20 ml %0,25 concentration bupivacain
• bupivacain+dexmedetomidine
Ultrasonography (USG) guided bilateral TAP block: 20 ml %0,25 concentration bupivacain+ 0.5 mcg/kg dexmedetomidine

Locations

Country	Name	City	State
Turkey	Turkey Dr.Abdurrahman Yurtaslan Ankara Oncology Train and Research Hospital	Ankara	Cankaya

Sponsors (1)

Lead Sponsor	Collaborator
Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Analgesic effectiveness of bupivacain and bupivacain+dexmedetomidine combination in colorectal cancer surgery	Numeric Rating Scales of two groups in postoperative period. The numeric rating scale (NRS) is a pain screening tool, commonly used to assess pain severity at that moment in time using a 0-10 scale, with zero meaning "no pain" and 10 meaning "the worst pain imaginable"	postoperative day two